2024-516164-28-00CompletedPhase 1
A double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of briquilimab in participants with allergic asthma.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 7 Nov 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- First submitted
- 18 Jul 2024
- Start date
- 30 Sept 2024
- Lead sponsor
- Jasper Therapeutics Inc.
- Diseases
- Asthma
- EU CT number
- 2024-516164-28-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 8
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Velocity Clinical Research Grosshansdorf GmbH | Grosshansdorf | Germany | Completed |
| The Fraunhofer Institute For Toxicology And Experimental Medicine ITEM | Hanover | Germany | Completed |
| IKF Pneumologie GmbH & Co. KG | Mainz | Germany | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.